Semaglutide, the active molecule in Novo Nordisk's Ozempic and Wegovy treatments, leads to considerable weight-loss in patients and thus can provide major help in managing diabetes and other medical problems related to obesity
The company is also testing the drug with every-other-month dosing
The original type, atrophic scars , shows up as skin depressions, including ice-pick scars (deep, narrow pits), boxcar scars (broad depressions with defined edges), and rolling scars (wave-like appearance) [17]
The company boasts that 5,377 members who used the $99 monthly subscription service for at least 26 weeks averaged a 15% loss in weight
Understanding these patterns helps patients push through the difficult early period of either medication without abandoning treatment prematurely